|
|
|
|
Lentiviral vector supply is often treated more like a raw material procurement line item. However, it sets your drug pipeline viability, through constrained supply, production cost, and manufacturing models that limit how far a therapy can scale. Here is what changes when the vector is treated as a cornerstone strategy from the first decision.
|
|
|
|
|
What happens when a vector company is built around a platform? COO Dr. Mike Kadan explains Vector BioMed's modular, purpose-built model, why it compresses the timelines the traditional CDMO approach stretches out, and what it means for programs planning distributed manufacturing.
|
|
|
|
|
Choosing a clinical candidate on limited vector screening is how cell and gene therapy programs end up rebuilding and ballooning in costs. Enter the LENTIVERSE™: LaunchSuite for CD19 and BCMA programs that shouldn't rebuild a vector that already exists, and VectorCraft for novel payloads screened for titer and function before you commit.
|
|
|
|
|
What happens when the vector, reagents, and cell process arrive as one ready-to-deploy system? This application note follows LaunchSuite into a clinical center: a fully characterized CGMP anti-CD19 vector, low-touch cell processing, and a tech transfer program the receiving team runs itself.
|
|
|
|
|
|
|
|
|
|
Established Target? Your Vector Is Already Built.
|
LENTIVERSE™ LaunchSuite pairs engineered lentiviral vectors with integrated reagents and a standardized cell manufacturing workflow, moving from patient starting material to finished CAR-T product in 7 days. Start with 1 mL aliquots, scale to CGMP supply, pre-IND documentation package included.
|
|
• Request Information
|
|
|
|
|
|
|
|
|
|
|
Complex Payload? Your Design Choices Won't Stay Upstream.
|
LENTIVERSE™ VectorCraft is custom lentiviral vector design with manufacturing foresight built in. Payload architecture, regulatory elements, and envelope selection are engineered against titer, potency, impurity profile, and future tech transfer, then screened on the same platform process used to manufacture.
|
|
• Request Information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vector BioMed spun out of Caring Cross to change the relationship therapy developers have with their vector supplier. LENTIVERSE™ is the result: one lentiviral vector platform, two paths to advance cures. LaunchSuite gives clinical institutions a ready-to-deploy route to point-of-care CAR-T on established targets. VectorCraft gives developers of novel therapies a custom vector engineered with the full development path in view. Both draw on decades of hands-on lentiviral vector experience, led by founder Dr. Boro Dropulić. See how LaunchSuite lets you manufacture where care happens, or how a streamlined custom program turns future therapies into product realities. Learn more.
|
|
|
